Article Text

Download PDFPDF

Genetics insight into the amyotrophic lateral sclerosis/frontotemporal dementia spectrum
  1. Ai-Ling Ji1,
  2. Xia Zhang2,3,4,5,
  3. Wei-Wei Chen2,3,4,5,
  4. Wen-Juan Huang2,3,4,5
  1. 1Department of Neurology, The Third People Hospital of Xuzhou, Xuzhou, China
  2. 2Department of Neurology, Xuzhou Central Hospital, Xuzhou, China
  3. 3The Affiliated Xuzhou Hospital of Medical College of Southeast University, Xuzhou, China
  4. 4Xuzhou Clinical School of Xuzhou Medical College, Xuzhou, China
  5. 5Xuzhou Clinical Medical College of Nanjing University of Chinese Medicine, Xuzhou, China
  1. Correspondence to Dr Wen-Juan Huang, Department of Neurology, Xuzhou Central Hospital, Xuzhou 221009, China; ftmlb8556215{at}


Recent genetic discoveries have dramatically changed our understanding of two major neurodegenerative conditions. Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are common, devastating diseases of the brain. For decades, ALS and FTD were classified as movement and cognitive disorders, respectively, due to their distinct clinical phenotypes. The recent identification of chromosome 9 open reading frame 72 (C9orf72) as the major gene causative of familial forms of ALS and FTD uncovered a new reality of a continuous FTD/ALS spectrum. The finding that up to 50% of all patients present some degree of ALS and FTD phenotypes supports this ALS/FTD continuum. Now >100 genes are known to contribute to ALS/FTD, with a few major contributors that are reviewed below. The low penetrance of C9orf72 mutations, its contribution to sporadic cases, and its combination with other genes support an oligogenic model where two or more genes contribute to disease risk, onset, progression and phenotype: from ‘pure’ ALS or FTD to combined ALS/FTD. These advances in the genetics of ALS/FTD will soon lead to a better mechanistic understanding of the pathobiology of the disease, which should result in the development of effective therapies in the near future.

  • Neurology
  • Neuromuscular disease
  • Genetics
  • Genetic screening/counselling
  • Genome-wide
View Full Text

Statistics from


  • Contributors W-JH conceived this review; A-LJ, XZ, W-WC and W-JH contributed to drafting the article, revising it critically for important intellectual content and approved the final version submitted to the journal. W-JH as the senior author is responsible for the final content and guarantor.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.